Back to search results

I3LUNG: Improving Lung Cancer Care with Immunotherapy

This study, called I3LUNG, is looking at how to better predict if immunotherapy will work for people with non-small cell lung cancer (NSCLC). Researchers are gathering information from 2200 patients to create a special tool that uses artificial intelligence (AI) to help doctors make more personalized treatment decisions. You might be able to join if you are 18 or older, have stage IIIB/C-IV NSCLC, and have received or are about to receive immunotherapy. The main goal is to see how many patients respond to treatment, measured at 8 weeks. The current status of this study is unclear.

Study design
This is an observational study, meaning researchers will collect information without giving specific treatments. It plans to include 2200 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Response to treatment will be measured at 8 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05537922

I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy

Recruiting
Not specifiedAges 18+Observational
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
~2,200 participants
Updated 2023-01-06 on ClinicalTrials.gov

At a glance

Recruiting sites
4 of 4 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Response Rate
Measured over 8 weeks (i.e. first radiological evaluation)

Conditions

Non Small Cell Lung Cancer
Lung Cancer Metastatic
Lung Cancer, Nonsmall Cell
Lung Adenocarcinoma

Explore related trials

Lung Non-Small Cell Carcinoma

Where it's being run

4 sites across 4 states
Illinois1
Greece1
Israel1
Spain1

Who to contact

Arsela Prelaj, MD
[email protected]
+39 022390 3647
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age \>/= 18 years.
Eastern Cooperative Oncology Group (ECOG) performance status \</= 2.
Histologically confirmed diagnosis of stage IIIB/C-IV Non-Small-Cell Lung Cancer
Received any line immunotherapy (maintenance therapy with Durvalumab is allowed) for retrospective cohort; clinical indication for frontline treatment with immunotherapy as first line treatment for prospective cohort.
Patients with CNS metastasis are allowed
Patients with driver genomic alterations are allowed (only for retrospective cohort)
Evidence of a personally signed and dated ICF indicating that the patient has been informed of and understands all pertinent aspects of the study before enrolment (only for prospective cohort)
Availability of at least one FFPE block for -omics data generation (only for prospective cohort)

Exclusion

Patients without minimal treatment information data to be included in the retrospective cohort
Prior treatment for advanced disease (only for prospective cohort)
Unavailability or inability to comply with the requested study procedures, including compilation of QoL questionnaires

What this trial measures

  • Response Rate8 weeks (i.e. first radiological evaluation)

    Prediction of response to immune checkpoint inhibitors in NSCLC